AU2017214761B2 - Proteinaceous compounds and uses therefor - Google Patents

Proteinaceous compounds and uses therefor Download PDF

Info

Publication number
AU2017214761B2
AU2017214761B2 AU2017214761A AU2017214761A AU2017214761B2 AU 2017214761 B2 AU2017214761 B2 AU 2017214761B2 AU 2017214761 A AU2017214761 A AU 2017214761A AU 2017214761 A AU2017214761 A AU 2017214761A AU 2017214761 B2 AU2017214761 B2 AU 2017214761B2
Authority
AU
Australia
Prior art keywords
pkc
amino acid
cell
proteinaceous molecule
acid residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017214761A
Other languages
English (en)
Other versions
AU2017214761A1 (en
Inventor
Peter MILBURN
Sudha RAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epiaxis Therapeutics Pty Ltd
Original Assignee
Epiaxis Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016900314A external-priority patent/AU2016900314A0/en
Application filed by Epiaxis Therapeutics Pty Ltd filed Critical Epiaxis Therapeutics Pty Ltd
Publication of AU2017214761A1 publication Critical patent/AU2017214761A1/en
Assigned to EPIAXIS THERAPEUTICS PTY LTD reassignment EPIAXIS THERAPEUTICS PTY LTD Request for Assignment Assignors: UNIVERSITY OF CANBERRA
Application granted granted Critical
Publication of AU2017214761B2 publication Critical patent/AU2017214761B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11013—Protein kinase C (2.7.11.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017214761A 2016-02-01 2017-02-01 Proteinaceous compounds and uses therefor Active AU2017214761B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016900314 2016-02-01
AU2016900314A AU2016900314A0 (en) 2016-02-01 Proteinaceous compounds and uses therefor
PCT/AU2017/050083 WO2017132728A1 (en) 2016-02-01 2017-02-01 Proteinaceous compounds and uses therefor

Publications (2)

Publication Number Publication Date
AU2017214761A1 AU2017214761A1 (en) 2018-08-02
AU2017214761B2 true AU2017214761B2 (en) 2024-02-01

Family

ID=59499146

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017214761A Active AU2017214761B2 (en) 2016-02-01 2017-02-01 Proteinaceous compounds and uses therefor

Country Status (8)

Country Link
US (1) US10487115B2 (https=)
EP (1) EP3411061A4 (https=)
JP (2) JP7341451B2 (https=)
CN (2) CN108883155A (https=)
AU (1) AU2017214761B2 (https=)
CA (1) CA3011870A1 (https=)
SG (1) SG11201806122YA (https=)
WO (1) WO2017132728A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019090390A1 (en) * 2017-11-08 2019-05-16 University Of Canberra Immunogenic compositions and uses therefor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015039187A1 (en) * 2013-09-18 2015-03-26 University Of Canberra Stem cell modulation ii

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
ATE285477T1 (de) 1995-06-07 2005-01-15 Inex Pharmaceutical Corp Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
US6291455B1 (en) 1996-03-05 2001-09-18 Zeneca Limited 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
EP1002091B1 (en) 1997-07-09 2012-02-29 Coridon Pty Limited Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
AUPP807899A0 (en) 1999-01-08 1999-02-04 University Of Queensland, The Codon utilization
WO2000036083A2 (en) * 1998-12-17 2000-06-22 La Jolla Institute For Allergy And Immunology Pkc-interacting cousin of trx (picot) polypeptides, polynucleotides, and methods of making and using them
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
NZ522074A (en) 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity
CN1255392C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管生成抑制剂的秋水仙醇衍生物
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
CA2405728A1 (en) 2000-07-31 2002-02-07 Dabur Research Foundation Lipid-peptide conjugates for treatment of cancer
AU2003236720A1 (en) 2002-06-14 2003-12-31 Altana Pharma Ag Substituted diaminopyrimidines
WO2004076654A1 (en) * 2003-02-28 2004-09-10 Novartis Ag Three-dimensional structure of the catalytic domain of protein c theta, methods and use thereof
CA2604243C (en) 2004-04-14 2015-11-24 Avirid, Inc. Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
KR100859972B1 (ko) 2006-02-20 2008-09-25 이화여자대학교 산학협력단 막투과 단백질 도메인 펩타이드
BR112013010926A2 (pt) * 2010-11-01 2016-08-23 Univ Technology Sidney agentes imunomoduladores e seus usos
DK2683419T3 (en) * 2011-03-11 2018-07-02 Vib Vzw Molecules and Methods for Inhibition and Detection of Proteins
AU2013323101C1 (en) 2012-09-27 2021-08-19 University Of British Columbia Peptide directed protein knockdown
CA2958704A1 (en) 2014-08-25 2016-03-03 University Of Canberra Compositions for modulating cancer stem cells and uses therefor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015039187A1 (en) * 2013-09-18 2015-03-26 University Of Canberra Stem cell modulation ii

Also Published As

Publication number Publication date
JP2019506167A (ja) 2019-03-07
SG11201806122YA (en) 2018-08-30
JP2022023949A (ja) 2022-02-08
WO2017132728A1 (en) 2017-08-10
JP7341451B2 (ja) 2023-09-11
AU2017214761A1 (en) 2018-08-02
EP3411061A4 (en) 2019-07-10
CN116082457A (zh) 2023-05-09
EP3411061A1 (en) 2018-12-12
US10487115B2 (en) 2019-11-26
US20190040103A1 (en) 2019-02-07
CN108883155A (zh) 2018-11-23
CA3011870A1 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
AU2019207534B2 (en) Proteinaceous molecules and uses therefor
AU2006291541B2 (en) Cell-permeable peptide inhibitors of the JNK signal transduction pathway
KR102373603B1 (ko) 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
US7662786B2 (en) Dolastatin 15 derivatives
WO2001027268A2 (en) Cell-permeable peptide inhibitors of the jnk signal transduction pathway
MX2011004019A (es) Conjugados de etoposido y doxorubicina para entrega de farmacos.
US9757473B2 (en) Cell-penetrating peptide and conjugate comprising same
ES2319454T9 (es) Péptidos con permeabilidad celular inhibidores de la ruta de transducción de señales de la JNK
WO2011044374A1 (en) Capcna peptide therapeutics for cancer
CN102140473A (zh) 抗肿瘤的核酸与多肽及其应用
AU2017214761B2 (en) Proteinaceous compounds and uses therefor
US20240294587A1 (en) K-ras inhibitor
KR100409264B1 (ko) 세포내 신호전달을 교란시키는 합성 펩티드
WO2022232567A2 (en) Cyclic peptide inhibitors of usp22
KR20250138134A (ko) 표적 단백질 분해자 및 세포 투과 펩타이드를 포함하는 융합 분자 및 이의 용도
AU2012203529B2 (en) Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway
HK1118841B (en) Cell-permeable peptide inhibitors of the jnk signal transduction pathway

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: EPIAXIS THERAPEUTICS PTY LTD

Free format text: FORMER APPLICANT(S): UNIVERSITY OF CANBERRA

FGA Letters patent sealed or granted (standard patent)